Aurora and 22nd century group license foundational biosynthesis ip to cronos group

Licensing deal set to assist in the advancement of research and development for cannabinoid biosynthesis edmonton, ab, dec. 14, 2021 /prnewswire/ - aurora cannabis inc. (nasdaq: acb) (tsx: acb) ("aurora"), the canadian company defining the future of cannabinoids worldwide, together with 22nd century group, inc. (nasdaq: xxii) ("22nd century") announced today a three-way non-exclusive agreement to license biosynthesis intellectual property to cronos group inc. (nasdaq: cron) (tsx: cron) ("cronos group"), intended to assist in the advancement of research and development on the biosynthesis of cannabinoids. biosynthesis, a process common in the pharmaceutical industry, involves using living micro-organisms to convert simple substances into complex compounds.
ACB Ratings Summary
ACB Quant Ranking